Food and Drug Administration assessment – K-Tropix

This store requires javascript to be enabled for some features to work correctly.

  • Home
  • About Us
    • Resources
    • Kava
    • Regulations
    • Nootropics
    • Recipes
  • Products
    • Pure Series Powders
      • Gold bali
      • Green borneo
      • Green maeng da
      • Green malay
      • Red bali
      • Red maeng da
      • Trainwreck
      • White borneo
      • White maeng da
      • White sumatra
    • Capsules
      • Energy
      • Original "OG"
      • Pure Series Capsules
    • Shots
      • Energy kratom shot
      • Kanna shot
      • Kava shot
      • Kava and kratom shot
      • Nano kratom shots
      • Original "OG" Shot
      • Pure Series Shots
      • Knetic Freedom Energy Shot
    • Gummies
  • Contact
  • Login
  • My account
ktropix-logo
  • Home
  • About Us
    • Resources
    • Kava
    • Regulations
    • Nootropics
    • Recipes
  • Products
    • Pure Series Powders
      • Gold bali
      • Green borneo
      • Green maeng da
      • Green malay
      • Red bali
      • Red maeng da
      • Trainwreck
      • White borneo
      • White maeng da
      • White sumatra
    • Capsules
      • Energy
      • Original "OG"
      • Pure Series Capsules
    • Shots
      • Energy kratom shot
      • Kanna shot
      • Kava shot
      • Kava and kratom shot
      • Nano kratom shots
      • Original "OG" Shot
      • Pure Series Shots
      • Knetic Freedom Energy Shot
    • Gummies
  • Contact
  • Login
  • My account
  • 0
ktropix-logo
Search 0 Cart
FREE SHIPPING ON ALL ORDERS OVER $65
Home / Health / Food and Drug Administration assessment
Access Denied
IMPORTANT! If you’re a store owner, please make sure you have Customer accounts enabled in your Store Admin, as you have customer based locks set up with EasyLockdown app. Enable Customer Accounts

Food and Drug Administration assessment

November 20, 2023
Food and Drug Administration assessment - K-Tropix

Food and Drug Administration assessment of Kratom


The FDA's assessment of kratom has been characterized by a series of concerns and regulatory actions aimed at addressing potential health risks associated with this botanical substance. In April 2019, the FDA issued a statement emphasizing that kratom had not received approval for any medical use. The agency raised concerns about the safety of kratom products available in the United States and continued to enforce an import alert, which allowed the confiscation of imported kratom supplies. This move underscored the FDA's commitment to ensuring the safety of products containing kratom that enter the U.S. market.

FDA’s regulation on Kratom

One significant development in this regulatory landscape occurred on April 4, 2018, when the FDA issued its first-ever mandatory recall due to concerns of salmonella contamination in various kratom-containing products. These products, manufactured by Triangle Pharmanaturals and marketed under the brand name 'Raw Form Organics,' tested positive for contamination, and the manufacturer did not comply with federal requests for voluntary recall. The FDA's Commissioner at the time, Scott Gottlieb, stressed that the recall was primarily driven by the imminent health risk posed by salmonella contamination, rather than other regulatory concerns. Consumers were strongly advised to discard such products promptly to mitigate potential serious health risks.

FDA's scrutiny of kratom

In February 2018, Commissioner Gottlieb further highlighted the opioid-like properties of kratom and reiterated that it should not be used for medical treatment or recreational purposes. The FDA's scrutiny of kratom extended to overseeing the voluntary destruction of kratom dietary supplements by a distributor in Missouri, signaling a proactive approach to regulating the substance. The agency encouraged all companies involved in kratom commerce to remove their products from the market, emphasizing the need for vigilance in addressing potential safety issues.

Food and Drug Administration evidence

In November 2017, the FDA voiced serious concerns over the marketing and effects of kratom use in the United States, including instances of death associated with its consumption. The agency emphasized that there was no reliable evidence to support the use of kratom as a treatment for opioid use disorder and highlighted the absence of FDA-approved therapeutic uses for the substance. These concerns underscored the significant safety issues linked to kratom use, further reinforcing the FDA's cautious stance on this botanical product.

Food and Drug Administration Public health

Overall, the FDA's assessments and actions regarding kratom reflect its commitment to protecting public health by addressing potential risks and safety concerns associated with this substance. These regulatory measures aim to ensure that consumers are informed and protected when it comes to the use of kratom-containing products.

If you're curious about kratom’s calming effects, check out How Kratom Supports Calm. Wondering how long it stays active? Read Kratom Duration Info.

Looking to explore premium kratom strains? Browse our White Sumatra Collection or Explore White Borneo.

Sources

C. Michael White. (2018). Pharmacologic and clinical assessment of kratom. American Journal of Health-System Pharmacy. Available at: https://academic.oup.com/ajhp/article-abstract/75/5/261/5102317?login=false

Papadis, A., et al. (2022). Assessment of the possible health risks associated with the consumption of botanical preparations of Mitragyna speciosa (kratom). EFSA Journal. Available at: https://efsa.onlinelibrary.wiley.com/doi/full/10.2903/j.efsa.2022.e200415

Scott Gottlieb, M.D. (2018). Statement from FDA Commissioner on the agency’s scientific evidence on the presence of opioid compounds in kratom, underscoring its potential for abuse. Available at: https://www.fda.gov/news-events/press-announcements/statement-fda-commissioner-scott-gottlieb-md-agencys-scientific-evidence-presence-opioid-compounds

Eastlack, S.C., et al. (2020). Kratom-Pharmacology, Clinical Implications, and Outlook: A Comprehensive Review. Pain Ther. Available at: https://link.springer.com/article/10.1007/s40429-023-00478-3

Singh, D., et al. (2017). Changing trends in the use of kratom (Mitragyna speciosa) in Southeast Asia. Hum Psychopharmacol. Available at: https://www.ncbi.nlm.nih.gov/books/NBK585120/

Gerlach, K.K., & Henningfield, J.E. (2019). Kratom as a substitute for opioids: Results from an online survey. Drug and Alcohol Dependence. Available at: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10243221/

Eggleston, W., et al. (2019). Kratom use and toxicities in the United States. Pharmacotherapy. Available at: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10243221/

[/su_spoiler]


Older post Newer post

Recent articles
  • Boost Your Kratom Experience: Natural Potentiators & Smart Lifestyle Hacks
    May 8, 2025
  • Sweat, Recovery & Kratom: A Gym-Goer’s Guide to Natural Relief
    May 8, 2025
  • Exploring Kratom’s Benefits for Natural Wellness Enthusiasts
    April 26, 2025
  • From One Habit to Another? Exploring the Overlap Between Alcohol Withdrawal and Kratom Dependency
    April 10, 2025
  • Does Kratom Lower Testosterone? A Science-Backed Analysis
    April 9, 2025
  • Kratom Detox Guide: How to Safely Cleanse Your System and Manage Withdrawal
    April 1, 2025
Invalid password
Enter
Footer-logo

KT OR 1, LLC 5305
River Rd. N STE B
Keizer, OR 97303

Quick links
  • About US
  • Blog
  • Terms & Conditions
  • Refund Policy
  • Privacy Policy
  • Shipping Policy
  • Become an Affiliate
  • Labs / Testing
  • Contact
Comunity
  • Facebook
  • Linkedin
  • Instagram
  • TikTok
  • YouTube
Need Help

1-877-KTROPIX
(587-6749)

sales@ktropix.com
Payment logos
  • © 2025, K-Tropix
  • © 2025, K-Tropix, LLC. All Rights Reserved.

Disclaimer: These statements and products presented on this website have not been evaluated by the Food and Drug Administration FDA. The products mentioned on this website are not intended to diagnose, prevent, treat or cure any diseases or health conditions. Therefore any information on this website is presented solely as the opinions of their respective authors who do not claim in any way shape or form to be medical professionals providing medical advice. Ktropix and its owners or employees cannot be held responsible for, and will not be liable for the inaccuracy or application of any information whatsoever herein provided. By purchasing our products you agree that you are aware and in compliance with your local county, state, or federal regulations. Must be 21 years or older to purchase mitragynine. The US FDA has not approved mitragynine as a dietary supplement. We do not ship to the following states, cities and counties in the US where mitragynine is banned: Alabama, Arkansas, Indiana, Rhode Island, Vermont, Wisconsin, Utah, Sarasota County, FL, Alcorn, Calhoun, Itawamba, Lowndes, Monroe, Noxubee, Prentiss, Tippah, Tishomingo, and Union County, MS, Corinth, Derma, Fulton, Guntown, Iuka, Mantachie, Marietta, New Albany, Okolona, Oxford, Pontotoc, Ripley, Saltillo, Senatobia and Vardaman, MS, Monument and Parker, CO, San Diego, CA, Jerseyville, IL, and Oceanside, CA.